New Law Aims to Improve Regulatory Transparency for Recently Approved Controlled Substances
Signed into law by President Obama, the Improving Regulatory Transparency for New Medical Therapies Act (HR 639) amends the Controlled Substances Act (CSA) so that newly approved controlled substances are scheduled more quickly and are available sooner for health care providers to prescribe to patients. Specifically, the law requires Drug Enforcement Administration (DEA) to make […]
Read More ›Prescription Drug Overdose Death Rates Drop in Oklahoma
In 2014, prescription drug overdose deaths in Oklahoma decreased by 5% from the previous year’s overdose death rate. Specifically, 510 people died in Oklahoma from prescription drug overdoses in 2014, compared with 538 people in 2013. The decreased rate represents the lowest rate in Oklahoma since 2007. State officials credit drug abuse prevention efforts, reports Drug […]
Read More ›Minnesota Board Uses PMP Data to Alert Prescribers of Potential Misuse, Support Assistance for Patients
After 10 months of sending unsolicited notices to about 2,400 health care providers alerting them of patients who might be “doctor shopping,” the Minnesota Board of Pharmacy found that 88% percent of these patients dropped off the alert list within one month after their prescribers were notified. The Board used the state’s prescription monitoring program […]
Read More ›AWARXE Prescription Drug Safety Program Launches a Redesigned Website, Site Granted a .Pharmacy Domain
The AWARXE® Prescription Drug Safety Program is pleased to announce the relaunch of its website to provide consumers and pharmacists with an easier way to find timely and relevant information on preventing the misuse and abuse of prescription drugs. In addition to the new look and easier navigation, the site has a new address: www.awarerx.pharmacy. […]
Read More ›PMP InterConnect Integration Projects Bring Data Into Pharmacy Workflow, Ohio Supports Additional Deployments With $1.5 M In Funding
Recognizing the importance of expanding the use of prescription monitoring program (PMP) data in pharmacists’ workflow to enhance prescription drug abuse and diversion prevention efforts, NABP has been working to integrate other PMP services with NABP PMP InterConnect®. Most recently, PMP Gateway – a service that works in tandem with PMP InterConnect – has been […]
Read More ›NABP Meets With Leaders Around the World to Collaborate on Solutions for Protecting Consumers From Illegal Online Drug Sellers
Today, the National Association of Boards of Pharmacy® (NABP®) issued a report discussing the importance of international collaboration in the fight against illegal online drug sellers. As detailed in the Internet Drug Outlet Identification Program Progress Report for State and Federal Regulators: October 2015, there is widespread agreement among multiple countries that Internet sales of […]
Read More ›White House Announces Plan to Address Opioid Abuse and Related Rise in Overdose Deaths
In response to the rise in deaths related to prescription opioid and heroin overdose, President Barack Obama has announced federal, state, local, and private sector efforts aimed to prevent and treat opioid addiction. As part of the plan, President Obama issued a memorandum directing federal departments and agencies to provide opioid prescribing training to federal […]
Read More ›NABP Supports Increasing Compounding Safety With Qualified Person Credentialing Program
With the goal of increasing compounding safety, CriticalPoint, LLC, has launched the Qualified Persons Credentialing Program (QPCP) for pharmacists at entities practicing compounding under sections 503A and 503B of the Drug Quality and Security Act (DQSA), Title I – Compounding Quality Act. NABP strongly believes that these pharmacists should be able to demonstrate knowledge, design […]
Read More ›FDA Announces DSCSA-Required Annual Reporting Database for Wholesale Distributor and Third-Party Logistics Providers
Under the Drug Supply Chain Security Act (DSCSA) of 2013, FDA is required to establish a public database to include information about wholesale distributors’ license information. Annual reporting to FDA is one requirement for wholesale distributors and third-party logistics providers to be authorized as defined in the DSCSA. Each line of the database represents a license […]
Read More ›FDA Issues Guidance on Adverse Event Reporting for Outsourcing Facilities
Food and Drug Administration (FDA) has published a guidance document, Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act, intended for firms registered with FDA under Section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) as human drug compounding outsourcing facilities. The guidance document […]
Read More ›